Literature DB >> 16307611

m-Chlorophenylpiperazine exacerbates perception of salicylate-induced tinnitus in rats.

Matthieu J Guitton1, Rémy Pujol, Jean-Luc Puel.   

Abstract

The serotonin receptor 5-HT2c agonist m-chlorophenylpiperazine (mCPP) has been widely used to induce anxiety-like states in animals and anxiety in humans. We here addressed the effect of an intraperitoneal injection of mCPP on the perception of tinnitus in a behavioural protocol based on an active avoidance paradigm. In control saline-treated animals, mCPP did not change compound action potential audiograms or measurable tinnitus. In contrast, mCPP to animals demonstrating salicylate-induced tinnitus exacerbated tinnitus perception by nearly twofold. We went on to test whether manipulation of the peripheral generator of tinnitus (i.e. the cochlea) could extinguish this exacerbated perception by applying the N-methyl-d-aspartate (NMDA) antagonist 7-chlorokynurenate (7-CK) into cochlear fluids using a 7-CK-soaked Gelfoam ball placed on the round window of each of the animals' two ears. In addition to blocking the tinnitus induced by salicylate alone, 50 microm of 7-CK clearly abolished tinnitus in animals receiving salicylate and an injection of mCPP. The demonstration that cochlear NMDA receptor blockade abolishes the exacerbated perception of tinnitus is highly relevant in terms of treatment. In addition to psychotherapeutic treatment that may help to attenuate an individual's perception of tinnitus, targeting cochlear NMDA receptors represents a promising therapeutic strategy, even in depressed or chronically anxious patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16307611     DOI: 10.1111/j.1460-9568.2005.04436.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  11 in total

1.  Vigabatrin, a GABA transaminase inhibitor, reversibly eliminates tinnitus in an animal model.

Authors:  Thomas J Brozoski; T Joseph D Spires; Carol A Bauer
Journal:  J Assoc Res Otolaryngol       Date:  2007-01-13

2.  PHARMACOLOGICAL TREATMENTS FOR TINNITUS: NEW AND OLD.

Authors:  R Salvi; E Lobarinas; W Sun
Journal:  Drugs Future       Date:  2009       Impact factor: 0.148

3.  A case report of onset of tinnitus following discontinuation of antidepressant and a review of the literature.

Authors:  Jane Clewes
Journal:  Prim Care Companion CNS Disord       Date:  2012-02-16

4.  Tinnitus psychopharmacology: A comprehensive review of its pathomechanisms and management.

Authors:  Michele Fornaro; Matteo Martino
Journal:  Neuropsychiatr Dis Treat       Date:  2010-06-24       Impact factor: 2.570

5.  Salicylate toxicity model of tinnitus.

Authors:  Daniel Stolzberg; Richard J Salvi; Brian L Allman
Journal:  Front Syst Neurosci       Date:  2012-04-20

6.  Predisposition for and prevention of subjective tinnitus development.

Authors:  Sönke Ahlf; Konstantin Tziridis; Sabine Korn; Ilona Strohmeyer; Holger Schulze
Journal:  PLoS One       Date:  2012-10-02       Impact factor: 3.240

7.  Tinnitus: pathology of synaptic plasticity at the cellular and system levels.

Authors:  Matthieu J Guitton
Journal:  Front Syst Neurosci       Date:  2012-03-08

8.  Sodium salicylate suppresses GABAergic inhibitory activity in neurons of rodent dorsal raphe nucleus.

Authors:  Yan Jin; Bin Luo; Yan-Yan Su; Xin-Xing Wang; Liang Chen; Ming Wang; Wei-Wen Wang; Lin Chen
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

9.  Blockade of cochlear NMDA receptors prevents long-term tinnitus during a brief consolidation window after acoustic trauma.

Authors:  Matthieu J Guitton; Yadin Dudai
Journal:  Neural Plast       Date:  2007       Impact factor: 3.599

10.  Noise-induced tinnitus using individualized gap detection analysis and its relationship with hyperacusis, anxiety, and spatial cognition.

Authors:  Edward Pace; Jinsheng Zhang
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.